» Articles » PMID: 11895039

14-3-3 Proteins in Lewy Bodies in Parkinson Disease and Diffuse Lewy Body Disease Brains

Overview
Specialties Neurology
Pathology
Date 2002 Mar 16
PMID 11895039
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Several components of Lewy bodies have been identified, but the precise mechanism responsible for the formation of Lewy bodies remains undetermined. The 14-3-3 protein family is involved in numerous signal transduction pathways and interacts with alpha-synuclein, which is a major constituent of Lewy bodies. To elucidate the role of 14-3-3 proteins in neuro-degenerative disorders associated with Lewy bodies, we performed immunohistochemical studies on 14-3-3 in brains from 5 elderly control subjects and from 10 patients with Parkinson disease (PD) or diffuse Lewy body disease (DLBD). In the normal controls, 14-3-3-like immunoreactivity was mainly observed in the neuronal somata and processes in various cortical and subcortical regions. In the PD and DLBD cases, a similar immunostaining pattern was found and immunoreactivity was generally spared in the surviving neurons from the severely affected regions. In addition, both classical and cortical Lewy bodies were intensely immunolabeled and some dystrophic neurites were also immunoreactive for 14-3-3. Our results suggest that 14-3-3 proteins may be associated with Lewy body formation and may play an important role in the pathogenesis of PD and DLBD.

Citing Articles

The BE (2)-M17 neuroblastoma cell line: revealing its potential as a cellular model for Parkinson's disease.

Carvajal-Oliveros A, Roman-Martinez C, Reynaud E, Martinez-Martinez E Front Cell Neurosci. 2024; 18:1485414.

PMID: 39659447 PMC: 11628309. DOI: 10.3389/fncel.2024.1485414.


14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity and toxicity.

Pattanayak R, Ekkatine R, Petit C, Yacoubian T Hum Mol Genet. 2024; 33(23):2071-2083.

PMID: 39324210 PMC: 11578116. DOI: 10.1093/hmg/ddae142.


A-Syn(ful) MAM: A Fresh Perspective on a Converging Domain in Parkinson's Disease.

Barbuti P Int J Mol Sci. 2024; 25(12).

PMID: 38928232 PMC: 11203789. DOI: 10.3390/ijms25126525.


Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson's Disease.

Giusto E, Maistrello L, Iannotta L, Giusti V, Iovino L, Bandopadhyay R J Parkinsons Dis. 2024; 14(3):495-506.

PMID: 38640169 PMC: 11091598. DOI: 10.3233/JPD-230402.


14-3-3τ as a Modulator of Early α-Synuclein Multimerization and Amyloid Formation.

Heesink G, van den Oetelaar M, Semerdzhiev S, Ottmann C, Brunsveld L, Blum C ACS Chem Neurosci. 2024; 15(9):1926-1936.

PMID: 38635928 PMC: 11066837. DOI: 10.1021/acschemneuro.4c00100.